 Benjamin Greenwood
Concepts (289)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Physical Conditioning, Animal | 22 | 2024 | 256 | 5.290 |
Why?
| | Extinction, Psychological | 12 | 2025 | 85 | 5.230 |
Why?
| | Fear | 19 | 2025 | 338 | 4.710 |
Why?
| | Stress, Psychological | 31 | 2024 | 1101 | 3.790 |
Why?
| | Corpus Striatum | 11 | 2025 | 167 | 3.760 |
Why?
| | Motor Activity | 25 | 2023 | 719 | 3.490 |
Why?
| | Helplessness, Learned | 14 | 2016 | 68 | 2.270 |
Why?
| | Running | 13 | 2017 | 230 | 1.900 |
Why?
| | Rats | 53 | 2025 | 5639 | 1.850 |
Why?
| | Substantia Nigra | 3 | 2025 | 57 | 1.690 |
Why?
| | Dopamine | 5 | 2025 | 303 | 1.630 |
Why?
| | Serotonin | 13 | 2019 | 323 | 1.620 |
Why?
| | Raphe Nuclei | 9 | 2019 | 110 | 1.610 |
Why?
| | Rats, Inbred F344 | 28 | 2019 | 264 | 1.520 |
Why?
| | Conditioning, Classical | 7 | 2024 | 102 | 1.320 |
Why?
| | Rats, Long-Evans | 7 | 2025 | 125 | 1.230 |
Why?
| | Dopaminergic Neurons | 5 | 2025 | 68 | 1.220 |
Why?
| | Receptors, Dopamine D1 | 4 | 2024 | 34 | 1.180 |
Why?
| | Memory Consolidation | 2 | 2018 | 12 | 1.150 |
Why?
| | Stress, Physiological | 12 | 2014 | 442 | 1.140 |
Why?
| | Prefrontal Cortex | 7 | 2024 | 305 | 1.080 |
Why?
| | Animals | 67 | 2025 | 36862 | 1.050 |
Why?
| | Reward | 5 | 2025 | 244 | 1.050 |
Why?
| | Brain | 13 | 2024 | 2675 | 1.030 |
Why?
| | Body Temperature Regulation | 2 | 2017 | 97 | 1.030 |
Why?
| | Receptor, Serotonin, 5-HT2C | 5 | 2013 | 15 | 1.020 |
Why?
| | TOR Serine-Threonine Kinases | 3 | 2020 | 412 | 1.000 |
Why?
| | Amygdala | 6 | 2017 | 191 | 1.000 |
Why?
| | Anxiety | 8 | 2019 | 1036 | 0.930 |
Why?
| | Conditioning, Operant | 4 | 2011 | 100 | 0.840 |
Why?
| | Sex Characteristics | 5 | 2025 | 765 | 0.820 |
Why?
| | Implosive Therapy | 2 | 2023 | 42 | 0.740 |
Why?
| | Proto-Oncogene Proteins c-fos | 8 | 2019 | 185 | 0.690 |
Why?
| | Exercise | 6 | 2025 | 2045 | 0.670 |
Why?
| | Behavior, Animal | 9 | 2020 | 497 | 0.670 |
Why?
| | Male | 60 | 2025 | 67560 | 0.670 |
Why?
| | Avoidance Learning | 3 | 2018 | 76 | 0.660 |
Why?
| | Hypothalamus | 2 | 2017 | 153 | 0.650 |
Why?
| | Serotonin Agents | 1 | 2018 | 9 | 0.610 |
Why?
| | N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2018 | 12 | 0.610 |
Why?
| | Physical Exertion | 4 | 2019 | 215 | 0.600 |
Why?
| | Electroshock | 12 | 2017 | 142 | 0.570 |
Why?
| | Hippocampus | 5 | 2017 | 895 | 0.540 |
Why?
| | Neurons | 7 | 2017 | 1588 | 0.530 |
Why?
| | Hypothermia | 1 | 2016 | 36 | 0.520 |
Why?
| | Ventral Tegmental Area | 1 | 2017 | 58 | 0.510 |
Why?
| | Rats, Sprague-Dawley | 15 | 2023 | 2486 | 0.500 |
Why?
| | RNA, Messenger | 12 | 2022 | 2839 | 0.490 |
Why?
| | Wakefulness | 1 | 2016 | 125 | 0.490 |
Why?
| | Neural Inhibition | 1 | 2016 | 169 | 0.480 |
Why?
| | Emotions | 3 | 2018 | 547 | 0.480 |
Why?
| | Analysis of Variance | 9 | 2017 | 1318 | 0.470 |
Why?
| | Neuronal Plasticity | 4 | 2016 | 290 | 0.470 |
Why?
| | Memory | 4 | 2020 | 255 | 0.470 |
Why?
| | Volition | 2 | 2017 | 34 | 0.460 |
Why?
| | Freezing Reaction, Cataleptic | 6 | 2017 | 22 | 0.450 |
Why?
| | Escape Reaction | 3 | 2012 | 62 | 0.440 |
Why?
| | Brain-Derived Neurotrophic Factor | 4 | 2016 | 133 | 0.410 |
Why?
| | Receptors, Dopamine D2 | 4 | 2018 | 98 | 0.380 |
Why?
| | Rats, Wistar | 3 | 2017 | 455 | 0.370 |
Why?
| | Receptors, Adrenergic, alpha-1 | 3 | 2010 | 45 | 0.370 |
Why?
| | Body Weight | 9 | 2020 | 985 | 0.360 |
Why?
| | Neostriatum | 2 | 2022 | 33 | 0.340 |
Why?
| | Limbic System | 1 | 2010 | 47 | 0.340 |
Why?
| | Circadian Rhythm | 4 | 2016 | 468 | 0.340 |
Why?
| | Association Learning | 1 | 2010 | 60 | 0.320 |
Why?
| | Receptor, Serotonin, 5-HT1A | 3 | 2016 | 38 | 0.320 |
Why?
| | Cognition | 2 | 2017 | 1169 | 0.310 |
Why?
| | Locomotion | 2 | 2012 | 106 | 0.310 |
Why?
| | Corticosterone | 7 | 2014 | 236 | 0.300 |
Why?
| | Fluvoxamine | 1 | 2008 | 17 | 0.290 |
Why?
| | Auditory Perception | 3 | 2017 | 115 | 0.280 |
Why?
| | Tetrodotoxin | 2 | 2017 | 37 | 0.270 |
Why?
| | Catecholamines | 3 | 2005 | 98 | 0.270 |
Why?
| | Stress Disorders, Post-Traumatic | 3 | 2023 | 844 | 0.260 |
Why?
| | Social Behavior | 4 | 2020 | 287 | 0.260 |
Why?
| | Norepinephrine | 2 | 2017 | 204 | 0.260 |
Why?
| | Exercise Therapy | 2 | 2008 | 437 | 0.260 |
Why?
| | Estrous Cycle | 1 | 2025 | 20 | 0.240 |
Why?
| | Receptor, Serotonin, 5-HT1B | 1 | 2005 | 5 | 0.240 |
Why?
| | Nucleus Accumbens | 2 | 2017 | 138 | 0.240 |
Why?
| | Depression | 2 | 2012 | 1408 | 0.230 |
Why?
| | Tyrosine 3-Monooxygenase | 3 | 2016 | 72 | 0.230 |
Why?
| | Acoustic Stimulation | 4 | 2015 | 316 | 0.220 |
Why?
| | Dopamine Agonists | 1 | 2024 | 40 | 0.220 |
Why?
| | Cues | 3 | 2018 | 315 | 0.220 |
Why?
| | Membrane Transport Proteins | 1 | 2005 | 162 | 0.210 |
Why?
| | HSP72 Heat-Shock Proteins | 4 | 2013 | 32 | 0.200 |
Why?
| | Ovariectomy | 1 | 2023 | 152 | 0.200 |
Why?
| | Genes, fos | 1 | 2003 | 36 | 0.200 |
Why?
| | Exercise Test | 2 | 2006 | 625 | 0.200 |
Why?
| | Neural Pathways | 3 | 2015 | 295 | 0.200 |
Why?
| | Adrenal Glands | 4 | 2015 | 78 | 0.190 |
Why?
| | Female | 10 | 2025 | 73052 | 0.190 |
Why?
| | Membrane Glycoproteins | 1 | 2005 | 500 | 0.190 |
Why?
| | Depressive Disorder | 3 | 2012 | 380 | 0.190 |
Why?
| | Time Factors | 8 | 2016 | 6818 | 0.190 |
Why?
| | In Situ Hybridization | 4 | 2012 | 316 | 0.190 |
Why?
| | Sympathetic Nervous System | 1 | 2003 | 182 | 0.180 |
Why?
| | Body Temperature | 3 | 2017 | 221 | 0.180 |
Why?
| | Dentate Gyrus | 3 | 2010 | 37 | 0.180 |
Why?
| | Nerve Tissue Proteins | 1 | 2005 | 596 | 0.180 |
Why?
| | Gene Expression Regulation | 6 | 2010 | 2608 | 0.170 |
Why?
| | Cytokines | 4 | 2016 | 2090 | 0.170 |
Why?
| | Appetite | 1 | 2020 | 69 | 0.160 |
Why?
| | Aminopyridines | 3 | 2009 | 99 | 0.160 |
Why?
| | Serotonergic Neurons | 1 | 2019 | 29 | 0.160 |
Why?
| | Tryptophan Hydroxylase | 1 | 2019 | 53 | 0.160 |
Why?
| | Ketamine | 1 | 2019 | 93 | 0.150 |
Why?
| | Sirolimus | 1 | 2020 | 275 | 0.150 |
Why?
| | Heart Rate | 3 | 2017 | 823 | 0.150 |
Why?
| | Microdialysis | 3 | 2015 | 51 | 0.140 |
Why?
| | 3,4-Dihydroxyphenylacetic Acid | 1 | 2017 | 19 | 0.140 |
Why?
| | Rats, Transgenic | 1 | 2017 | 19 | 0.140 |
Why?
| | Decision Making | 1 | 2025 | 898 | 0.140 |
Why?
| | Estrus | 1 | 2017 | 11 | 0.140 |
Why?
| | Eating | 1 | 2020 | 379 | 0.140 |
Why?
| | Citalopram | 1 | 2017 | 29 | 0.140 |
Why?
| | Indoles | 3 | 2009 | 410 | 0.130 |
Why?
| | Sodium Channel Blockers | 1 | 2016 | 24 | 0.130 |
Why?
| | Lactoferrin | 1 | 2016 | 31 | 0.130 |
Why?
| | Exercise Movement Techniques | 1 | 2016 | 7 | 0.130 |
Why?
| | Skin Temperature | 1 | 2016 | 30 | 0.130 |
Why?
| | Secondary Prevention | 1 | 2018 | 234 | 0.130 |
Why?
| | Psychological Tests | 1 | 2017 | 141 | 0.130 |
Why?
| | Prebiotics | 1 | 2016 | 27 | 0.130 |
Why?
| | Cold Temperature | 1 | 2017 | 178 | 0.130 |
Why?
| | Fibroblast Growth Factor 2 | 2 | 2006 | 87 | 0.130 |
Why?
| | Sleep, REM | 1 | 2016 | 33 | 0.130 |
Why?
| | Vaccines, Inactivated | 1 | 2016 | 68 | 0.120 |
Why?
| | Models, Neurological | 1 | 2018 | 243 | 0.120 |
Why?
| | Bacterial Vaccines | 1 | 2016 | 63 | 0.120 |
Why?
| | Neuroglia | 1 | 2017 | 173 | 0.120 |
Why?
| | Energy Metabolism | 2 | 2020 | 920 | 0.120 |
Why?
| | Random Allocation | 2 | 2014 | 353 | 0.120 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2016 | 145 | 0.120 |
Why?
| | Mycobacterium | 1 | 2016 | 109 | 0.110 |
Why?
| | Recurrence | 1 | 2018 | 1059 | 0.110 |
Why?
| | Neuralgia | 1 | 2016 | 133 | 0.110 |
Why?
| | Interleukin-18 | 2 | 2012 | 237 | 0.110 |
Why?
| | Adrenocorticotropic Hormone | 3 | 2010 | 142 | 0.110 |
Why?
| | Anxiety Disorders | 2 | 2008 | 374 | 0.110 |
Why?
| | Interleukin-1beta | 2 | 2012 | 372 | 0.110 |
Why?
| | Humans | 10 | 2025 | 137294 | 0.110 |
Why?
| | Adipose Tissue, White | 1 | 2013 | 41 | 0.110 |
Why?
| | Colitis | 1 | 2016 | 266 | 0.100 |
Why?
| | Sex Factors | 1 | 2019 | 2073 | 0.100 |
Why?
| | Disease Models, Animal | 5 | 2016 | 4284 | 0.100 |
Why?
| | Phosphorylation | 1 | 2017 | 1759 | 0.100 |
Why?
| | Serotonin 5-HT2 Receptor Agonists | 2 | 2008 | 6 | 0.090 |
Why?
| | Pituitary-Adrenal System | 2 | 2010 | 162 | 0.090 |
Why?
| | Chemokines | 1 | 2012 | 228 | 0.090 |
Why?
| | Hypothalamo-Hypophyseal System | 2 | 2010 | 197 | 0.090 |
Why?
| | Locus Coeruleus | 1 | 2011 | 23 | 0.090 |
Why?
| | Immunoglobulin M | 2 | 2003 | 288 | 0.090 |
Why?
| | Inflammasomes | 1 | 2012 | 128 | 0.090 |
Why?
| | Receptors, Opioid, delta | 1 | 2010 | 10 | 0.090 |
Why?
| | Glucocorticoids | 1 | 2015 | 596 | 0.080 |
Why?
| | Stress Disorders, Traumatic | 1 | 2009 | 23 | 0.080 |
Why?
| | Morphine | 1 | 2011 | 160 | 0.080 |
Why?
| | CA1 Region, Hippocampal | 1 | 2009 | 52 | 0.080 |
Why?
| | Serotonin 5-HT2 Receptor Antagonists | 1 | 2008 | 10 | 0.080 |
Why?
| | Signal Transduction | 2 | 2020 | 5078 | 0.080 |
Why?
| | Diet | 1 | 2016 | 1275 | 0.070 |
Why?
| | Chemokine CCL2 | 3 | 2013 | 115 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2516 | 0.070 |
Why?
| | Up-Regulation | 3 | 2012 | 844 | 0.070 |
Why?
| | Habituation, Psychophysiologic | 1 | 2008 | 55 | 0.070 |
Why?
| | Reaction Time | 1 | 2010 | 416 | 0.070 |
Why?
| | Reinforcement Schedule | 1 | 2007 | 31 | 0.070 |
Why?
| | Nerve Net | 1 | 2010 | 258 | 0.070 |
Why?
| | Interleukin-10 | 3 | 2013 | 302 | 0.070 |
Why?
| | Receptors, Catecholamine | 1 | 2006 | 4 | 0.070 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2006 | 46 | 0.060 |
Why?
| | Spleen | 3 | 2003 | 514 | 0.060 |
Why?
| | Fluoxetine | 1 | 2006 | 54 | 0.060 |
Why?
| | Bacteria | 1 | 2012 | 858 | 0.060 |
Why?
| | Brain Chemistry | 1 | 2005 | 118 | 0.060 |
Why?
| | Physical Endurance | 1 | 2006 | 277 | 0.060 |
Why?
| | Escherichia coli Infections | 1 | 2005 | 111 | 0.060 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2005 | 75 | 0.060 |
Why?
| | Psychomotor Performance | 1 | 2007 | 313 | 0.060 |
Why?
| | Interleukin-6 | 3 | 2013 | 778 | 0.060 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2004 | 29 | 0.060 |
Why?
| | Fatigue | 1 | 2006 | 328 | 0.050 |
Why?
| | Down-Regulation | 1 | 2006 | 658 | 0.050 |
Why?
| | Central Nervous System | 1 | 2006 | 258 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2008 | 2052 | 0.050 |
Why?
| | Encephalitis | 1 | 2005 | 137 | 0.050 |
Why?
| | Receptors, Serotonin, 5-HT1 | 1 | 2003 | 7 | 0.050 |
Why?
| | CD5 Antigens | 1 | 2003 | 10 | 0.050 |
Why?
| | Immunohistochemistry | 3 | 2019 | 1734 | 0.050 |
Why?
| | Receptors, Serotonin | 1 | 2003 | 34 | 0.050 |
Why?
| | CD11 Antigens | 1 | 2003 | 30 | 0.050 |
Why?
| | Analgesics, Opioid | 1 | 2011 | 994 | 0.050 |
Why?
| | B-Lymphocyte Subsets | 1 | 2002 | 75 | 0.050 |
Why?
| | Heat-Shock Proteins | 1 | 2002 | 142 | 0.050 |
Why?
| | Stem Cells | 1 | 2006 | 593 | 0.050 |
Why?
| | Interleukin-1 | 1 | 2005 | 964 | 0.040 |
Why?
| | Immune System | 1 | 2002 | 177 | 0.040 |
Why?
| | Electric Stimulation | 2 | 2013 | 264 | 0.040 |
Why?
| | Immunization | 2 | 2016 | 411 | 0.040 |
Why?
| | Mice | 2 | 2016 | 17774 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2003 | 846 | 0.030 |
Why?
| | Energy Intake | 1 | 2020 | 484 | 0.030 |
Why?
| | Receptors, Purinergic P2X5 | 1 | 2016 | 4 | 0.030 |
Why?
| | Activating Transcription Factor 3 | 1 | 2016 | 5 | 0.030 |
Why?
| | Excitatory Amino Acid Transporter 2 | 1 | 2016 | 16 | 0.030 |
Why?
| | p21-Activated Kinases | 1 | 2016 | 15 | 0.030 |
Why?
| | Sciatic Neuropathy | 1 | 2016 | 29 | 0.030 |
Why?
| | Nitrites | 1 | 2016 | 84 | 0.030 |
Why?
| | Ganglia, Spinal | 1 | 2016 | 77 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2002 | 827 | 0.030 |
Why?
| | Gene Expression | 2 | 2014 | 1501 | 0.030 |
Why?
| | Microfilament Proteins | 1 | 2016 | 131 | 0.030 |
Why?
| | Constriction, Pathologic | 1 | 2016 | 242 | 0.030 |
Why?
| | Functional Laterality | 1 | 2016 | 224 | 0.030 |
Why?
| | Hyperalgesia | 1 | 2016 | 123 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 283 | 0.030 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2016 | 151 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 2016 | 218 | 0.030 |
Why?
| | Adrenalectomy | 1 | 2015 | 68 | 0.030 |
Why?
| | Photoperiod | 1 | 2015 | 52 | 0.030 |
Why?
| | Enkephalins | 1 | 2014 | 20 | 0.030 |
Why?
| | Dynorphins | 1 | 2014 | 9 | 0.030 |
Why?
| | Receptor, Adenosine A1 | 1 | 2014 | 10 | 0.030 |
Why?
| | Receptor, Adenosine A2A | 1 | 2014 | 20 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 851 | 0.030 |
Why?
| | Cell Count | 2 | 2006 | 323 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2016 | 558 | 0.030 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2016 | 387 | 0.030 |
Why?
| | Telemetry | 1 | 2013 | 40 | 0.030 |
Why?
| | Peritoneum | 2 | 2003 | 43 | 0.030 |
Why?
| | Caspase Inhibitors | 1 | 2012 | 81 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2025 | 5769 | 0.020 |
Why?
| | Area Under Curve | 1 | 2013 | 315 | 0.020 |
Why?
| | Caspase 1 | 1 | 2012 | 143 | 0.020 |
Why?
| | Adaptation, Physiological | 2 | 2006 | 549 | 0.020 |
Why?
| | Uric Acid | 1 | 2012 | 163 | 0.020 |
Why?
| | Lymph Nodes | 2 | 2003 | 493 | 0.020 |
Why?
| | 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 2009 | 8 | 0.020 |
Why?
| | Radioimmunoassay | 1 | 2010 | 173 | 0.020 |
Why?
| | Restraint, Physical | 1 | 2010 | 72 | 0.020 |
Why?
| | Serotonin Receptor Agonists | 1 | 2009 | 26 | 0.020 |
Why?
| | Serotonin Antagonists | 1 | 2009 | 32 | 0.020 |
Why?
| | Noise | 1 | 2010 | 67 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2012 | 886 | 0.020 |
Why?
| | Injections, Intraperitoneal | 1 | 2008 | 115 | 0.020 |
Why?
| | Young Adult | 1 | 2025 | 13163 | 0.020 |
Why?
| | Pyrazines | 1 | 2008 | 91 | 0.020 |
Why?
| | Organ Size | 1 | 2008 | 477 | 0.020 |
Why?
| | Thymus Gland | 1 | 2008 | 313 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2009 | 844 | 0.020 |
Why?
| | Biogenic Monoamines | 1 | 2006 | 16 | 0.020 |
Why?
| | Gyrus Cinguli | 1 | 2006 | 87 | 0.020 |
Why?
| | Tail | 1 | 2006 | 28 | 0.020 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2006 | 26 | 0.020 |
Why?
| | Bromodeoxyuridine | 1 | 2006 | 80 | 0.020 |
Why?
| | Piperazines | 1 | 2008 | 350 | 0.020 |
Why?
| | Labetalol | 1 | 2005 | 6 | 0.020 |
Why?
| | Prazosin | 1 | 2005 | 23 | 0.020 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2006 | 100 | 0.020 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2005 | 34 | 0.020 |
Why?
| | Propranolol | 1 | 2005 | 50 | 0.020 |
Why?
| | Behavior | 1 | 2006 | 92 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2016 | 5753 | 0.010 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2005 | 323 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 2003 | 150 | 0.010 |
Why?
| | Hemocyanins | 1 | 2002 | 62 | 0.010 |
Why?
| | Cell Survival | 1 | 2006 | 1119 | 0.010 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2004 | 198 | 0.010 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2002 | 60 | 0.010 |
Why?
| | Adult | 1 | 2025 | 37724 | 0.010 |
Why?
| | Neuropsychological Tests | 1 | 2006 | 1055 | 0.010 |
Why?
| | Adaptation, Psychological | 1 | 2006 | 655 | 0.010 |
Why?
| | Leukocyte Count | 1 | 2002 | 331 | 0.010 |
Why?
| | Adjuvants, Immunologic | 1 | 2002 | 226 | 0.010 |
Why?
| | Blood Proteins | 1 | 2002 | 252 | 0.010 |
Why?
| | Lymphocytes | 1 | 2002 | 395 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2003 | 1184 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2006 | 2479 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 2002 | 886 | 0.010 |
Why?
| | Escherichia coli | 1 | 2002 | 814 | 0.010 |
Why?
| | Skin | 1 | 2002 | 751 | 0.010 |
Why?
| | Myocardium | 1 | 2002 | 1002 | 0.010 |
Why?
| | Neutrophils | 1 | 2002 | 1236 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2002 | 4197 | 0.010 |
Why?
| | Liver | 1 | 2002 | 1941 | 0.010 |
Why?
| | Inflammation | 1 | 2002 | 2836 | 0.010 |
Why?
|
|
Greenwood's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|